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Background
Tuberculosis remains one of the most infectious diseases worldwide especially with the HIV pandemic. It is a cause of high morbidity and 
mortality in developing countries including Nigeria. Reasons contributing to high morbidity and mortality include high defaulting rate and 
treatment interruption. Several studies had evaluated the treatment outcome of tuberculosis but there is paucity of published literature on the 
outcome of treatment interruption especially in this environment. This study thus assessed the outcome of treatments and interruption 
among patients assessing DOTS regimen in a tertiary hospital located in a semi urban area in south-western Nigeria.
Methodology
The study was a review of TB register of the federal medical centre,Owo from its inception in 2008  to  2011. All the patients that have 
completed at least one course of chemotherapy (defined as 8 months of anti-tuberculosis treatment- 2months intensive phase and 6 months 
continuation phase) were included. Treatment outcome and interruption were defined in accordance with World Health Organisation (WHO) 
recommendations. Data were analysed with SPSS version 17. 
Results
A total of 400 patients were included. The mean age of patients was 36.8 ± 16.8 years and 56.3% were male. Majority, (79.7%) were adults aged 
19-64 years, 12.5% were in the paediatric age group and 7.8% were elderly. Less than half, 45.3% had TB/HIV co-infection. Regarding   
treatment outcome of tuberculosis, 75.5% were cured, 14.8% died, 4% relapsed and 3% defaulted. A little above one-fifth, 21 (5.3%) had 
treatment interruption among whom 9 (42.9%) were successfully traced and completed treatment. Significantly, higher proportion of those 
that had treatment interruption died, 54.1% compared with their counterpart, 14.9%, (p<0.001) and had relapse. (14.3% versus 3.4%, p = 0.01).
Conclusion
A high rate of tracking failure among patients with treatment interruption was found in the study. In addition, mortality and morbidity were 
higher among patients with treatment interruption. A more concerted effort is needed in tracking / tracing patients with treatment interruption 
in order to reduce morbidity and mortality among TB patients assessing treatment.  
ABSTRACT
INTRODUCTION
Eastern Mediterranean Region (6%), the European 
1, 2Region (5%) and the Region of the Americans (3%).   
In Nigeria, tuberculosis (TB) is a serious public health 
problem with more than 460,000 estimated new cases 
3in 2007.  It ranks fourth out of the 22 countries 
designated by the WHO with the highest burden of TB 
1globally behind India, China and Indonesia.  According 
to the WHO Report 2009, the number of new cases of 
TB in 2007 was 311 per 100,000 population and 
number of prevalence cases of TB was 521 per 
1,3100,000.  
Poor compliance with treatment is thus a major 
impediment to effective tuberculosis (TB) 
chemotherapy worldwide and is one of the major 










uberculosis remains one of the most infectious 
diseases worldwide especially with the HIV 
pandemic. In spite of effective therapy, it is still T
a major health problem and it remains a cause of high 
morbidity and mortality in developing countries.
Globally, there were an estimated 9.27 million incident 
cases of TB in 2007. This is an increase from 9.24 
million cases in 2006, 8.3 million cases in 2000 and 
6.6 million cases in 1990. Most of the estimated 
numbers of cases in 2007 were in Asia (55%) and 
Africa (31%), with small proportion of cases in the 
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 4 drug resistance and relapse thus accounting for one of 
the most serious problem in TB control. The largest 
cause of unsuccessful treatment was 'defaulters' 
which is defined as 'a patient who interrupted 
treatment for two months or more after the date of the 
5, 6last attendance during the course of treatment.'  
Treatment interruptions on the other hand is defined 
as failure to report for or receive treatment for two 
consecutive days during the intensive phase, or failure 
to collect drugs for two weeks after the expected date 
6during the continuation phase.  Moreover, patients 
that interrupt treatment remain infectious and 
constitute a danger to their families and the 
community, a situation that is exacerbated by the 
organism being resistant to first line drugs. 
Mycobacterium tuberculosis has shown a propensity 
to mutate towards drug resistance, and defaulting 
patients have delayed sputum conversion and almost 
invariably relapse, often with a drug resistant strain, 
thus increasing the cost of treatment and may 
7 eventually lead to death.  In Nigeria, 1.8% of newly 
diagnosed TB patients were MDR-TB while 9.4% of 
1MDR-TB were among previously treated TB patients.  
Retreatment requires more expensive drugs producing 
a greater financial burden on either the patient or 
8 public health delivery system. The development of 
drug resistance may be mainly attributed to 
incomplete or inadequate treatment of patients with 
TB, inappropriate prescribing by providers, 
interruption of drug supply, failure to support 
patients on treatment, lack of infection control 
9precautions, and poor compliance with treatment. 
The key elements in tuberculosis (TB) control are to 
detect the disease as early as possible and to ensure that 
those diagnosed complete their treatment and get 
8cured.  In essence, this will interrupt transmission of 
TB to others and prevent the tubercle bacilli from 
becoming drug resistant. Incomplete treatment may 
result in excretion of bacteria that may also acquire 
drug resistance and cause increased morbidity and 
mortality. Treatment outcome results serves as a tool 
to control the quality of TB treatment provided by the 
health care system. However, several studies have 
looked into treatment outcomes of tuberculosis 
treatment but there is paucity of published literature 
on the outcomes of treatment interruption. This 
study therefore assessed the treatment outcomes of 
treatment interruption among patients assessing anti-
A total of 400 patients who had completed a course of 
anti-TB were reviewed. The mean age of patients was 
36.8 ± 16.8 years.
TB in a tertiary care centre in SW Nigeria during the 
10period 2008-2011.  
METHODOLOGY
The study was a review of TB register from its 
inception in 2008 to 2011. All the patients that have 
completed at least one course of anti-tuberculosis 
drugs [8 months of anti-tuberculosis treatment – 
two(2) months of intensive phase and six(6) months 
of continuation phase] were included. The study was 
conducted in Federal Medical Centre, Owo located in 
Owo local government area of Ondo State, Nigeria. 
The hospital provides health care at primary, 
secondary, tertiary level to the people within the 
catchment area which are Ondo, Kogi, Edo, Ekiti and 
Osun State. Treatment outcomes and interruption 
were defined in accordance with the WHO 
recommendations. Those that interrupted treatment 
for two (2) consecutive days or more during intensive 
phase, two (2) weeks or more during continuation 
phase and those that interrupted treatment for two (2) 
months or more after the date of the last attendance 
from the last treatment (defaulters) were regarded as 
having interrupted treatment. Data were analysed 
with SPSS version 17. Continuous variables were 
summarized using mean and standard deviation. 
Association between categorical variables was tested 
using Chi-square test at 5% level of significance.
RESULTS
Sex distribution of patients
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Table 1 shows the age group and marital status 
of patients. Majority, (79.7%) were adults aged 
19-64 years, 12.5% were in the paediatric age 
group and 7.8% were elderly. Majority, 322 
(80.5%) were married.
Effective tuberculosis (TB) treatment has been shown 
to have a significant effect on the control of TB. 
Completion of treatment of active cases is therefore the 
11 most important priority of TB control programs.
Guidelines suggest a target treatment completion rate 
12of 85% for infectious cases.  Any treatment outcome 
in which a cure is not established, i.e. sputum 
conversion to negative among active TB cases, will 
pose a danger to the community; hence, prevention of 
Overwhelming majority of the patients, 379 (94.8%) 
had pulmonary TB among whom 355 (93.7%) had 
positive sputum AFB (table 2).
Age distribution of patients
Table 1: Distribution of patients by age and marital status
AGE AND MARITAL STATUS 
N = 400 
FREQUENCY PERCENTAGE 
Age group   
=18 (Paediatrics) 50 12.5 
19-64 (Adults) 319 79.7 
=65 (Elderly) 31 7.8 
Marital Status   
Married 322 80.5 
Single 78 19.5 
 
Type of lesion and report of sputum AFB
Table 2: Distribution of patients by type of lesion 
and sputum AFB
Variables Frequency Percentage 
Type of lesion (N = 400)   
Pulmonary 379 94.8 
Extra pulmonary 21 5.2 
Sputum AFB (N = 397)   
Positive 355 93.7 
Negative 24 6.3 
 
TB/HIV co-infection
Figure 2 shows the proportion of patients with TB/HIV 
co-infection. Less than half, 45.3% had TB/HIV co-infection.
Outcomes of TB treatment
About 76% were cured, 14.8% died, 4% relapsed and 
3% defaulted (Table 3).
Table 3: Distribution of patients by outcome 
of TB treatment
Outcomes of treatment Frequency Percentage 
Cured 302 75.5 
Died 59 14.8 
Relapsed 16 4.0 
Defaulted 12 3.0 
Transferred 7 1.8 
Total 396 99 
 Others 4 (1%)
Treatment interruption
Table 4 shows the proportion of patients with treatment 
interruption. About one-fifth, 5.3% had treatment 
interruption among whom 9 (42.9%) were successfully 
traced and completed treatment.
Table 4: Distribution of patients by treatment interruption
Treatment interruption Frequency Percentage 
Yes 21 5.3 
No 379 94.7 
Total 400 100 
 
Association between treatment interruption and 
outcomes of treatment (death and relapse)
Significantly, higher proportion of those that had 
treatment interruption died, 54.1% compared with 
those that did not die, 14.9% (p < 0.001) and had 
relapse, 14.3% compared with those without relapse, 
3.4% (p = 0.01).
DISCUSSION
54
Nigerian Journal of Medicine, Vol. 23  No.1,   January-March, 2014,  ISSN 1115-2613
such occurrences is necessary to maximize the 
efficiency of TB control programs. The mean age of 
patients in this study was 36.8±16.8years. This 
finding that TB primarily affects the young adults 
was consistent with previous reports in developing 
13,14,15countries,   this accounts for most of the 
productive years, hence, TB takes its toll on the 
economy of a nation. However, TB has been reported 
to be two-to-four times more prevalent among the 
16elderly age group in developed countries.
   The observation that a greater percentage (56.3%) of 
the patients were males is consistent with other 
17,18reports  that revealed males are at an increased risk 
of a poor treatment  outcome compared to females. 
This may be attributed to the prevalence of high risk 
behaviors among the men. Lienhardt et al, in 1998, 
reported that females were more likely to achieve a 
19cure than their male counterparts. Similarly, Diel et 
al, attributed poor treatment outcomes, such as 
20default, failure, and death, to males.
Among the 400 patients, 322 (80.5%) were married, 
2178 (19.5%) single, as also observed by Sweta  et al,  
this may be due to the fact that partners tend to infect 
each other.  379(94.8%) patients had pulmonary 
tuberculosis, while 21(5.2%) had extrapulmonary 
tuberculosis, compared with 179 (89.05%) suffered 
from Pulmonary Tuberculosis, eight were cases of 
extrapulmonary Tuberculosis (EPTB); while 14 had 
both pulmonary as well as extra-pulmonary 
21
tuberculosis.  Of those with pulmonary Tuberculosis, 
355(93.7%) were found to be smear positive, and 
24(6.3%) were found to be smear negative, this is close 
22,23to what was found in other studies.
 TB is the major opportunistic infection and leading 
24,25cause of death among people living with AIDS.   
Less than half, 45.3% of patients had TB/HIV co-
infection, while 54.7% were HIV negative.  The rising 
TB/HIV epidemic no doubt impacts negatively on 
AIDS and TB control programs in many ways. The im-
pact ranges from increased caseload of active TB 
attributable to HIV, HIV-related morbidity and 
mortality in TB patients, higher default rates and low 
cure rates, high rate of adverse drug reactions, 
increased risk of TB transmission and delay of access 
to health services for TB suspects due to the stigma of 
26HIV/AIDS.  This result is however high compared to 
28.9% positive and 71.1% negative reported by Bello in 
his  study on the challenges of DOTS implementation 
strategy in the treatment of tuberculosis in a tertiary 
15health institution in Ilorin.
The cure rate of 75.5% in this study is closely related to 
18what was found in the Fatiregun et al study  in which 
the cure rate was 76.6%, but below the recommended 
14 target of 85% by the WHO. The cure rate of 73% was 
what was documented among pulmonary TB patients 
in the Obafemi Awolowo University Teaching 
13Hospital (OAUTH) in Ile Ife.  The findings were also 
closely related to what was found in another study 
conducted at the northern Nigeria where a cure rate of 
70.5% was reported among males and 78.5% among 
15females.  However, the University of Maiduguri 
Teaching Hospital DOTS program had recorded 85.5% 
success rate in the treatment of PTB over the studied 
period-three(3) years. Though the success rate reached 
27the rate projected for Nigeria,  it was lower than 90-
2895% global success rate of treatment.   59(14.8%) died 
during the study period, compared with 41(2.4%) as 
23recorded by Yakubu et al,  and this could be as result 
of the higher cure rate in their study. Of those that 
died, a higher proportion was found in those that had 
treatment interruption. However, N Njepuome et al 
recorded that death rate was higher among the dually 
infected patients (25.7%) compared with HIV-negative 
patients (15.5%); the difference was also highly 
22significant (p=0.000).
The default rate was found to be 12(3.0%), this is low 
23when placed alongside with studies; it was 12.1%  
15and 22.3% in males and 14.3% in females  
respectively. This could be because the sample size in 
these studies were much larger than in our study, but 
these default rates are higher than the reported 5% 
global default rate.
Out of the 400 patients, 21(5.3%) had treatment 
interruption, out of which an higher proportion died 
compared with those without treatment interruption 
54.1% versus 14.9%; and 14.3% had relapse compared 
with 3.4% in those without interruption. Various 
reasons have been attributed to interruption of 
29treatment by various studies; Kaona et al  found that 
29.8% of TB patients failed to comply with anti-TB 
once they started feeling better. 
Social problems and feeling of improvement were the 
top two reasons for patients to default in study by 
30 31Demissie et al.  In another survey by Tissera relief 
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from symptoms (13%) emerged as the most common 
reason for treatment interruption. However, in a 
32study by Jaggarajamma et al , relief from symptoms 
was found to be the third commonest reason for 
discontinuation of treatment (20%).
These reasons are also very likely to hold true in our 
own study as most of the results obtained were very 
comparable.
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Due to the retrospective nature of the study, data 
extracted were through the TB register.
Socio-economic status and educational background 
are some of the factors that we would have loved to 
associate with treatment interruption, but these were 
not captured in the TB register.
The accurate timing of interruption of treatment as 
well as reasons for the interruption of treatment could 
not be elicited from the study.
For subsequent studies on this subject, there's a need to 
establish the reasons for treatment interruption, so as 
to be able to stem tide of such in those just starting 
anti-tuberculous medications.  
Suggestions for further studies
There's also a need to identify possible risk factors that 
may predispose patients to interrupting treatment 
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